Dr. Jakub Tolar, president, CEO and executive dean of the Baylor College of Medicine, says the new fund will bridge the gap between academic funding and private investment. Photo courtesy BCM

Houston’s Baylor College of Medicine just unveiled a new venture capital fund that backs early-stage biotech startups—and it’s already made its first investment.

BCM Legacy Fund I, funded by philanthropies, invested an undisclosed amount in Houston biotech startup Nemea Therapeutics. Nemea, a spinout of the Baylor College of Medicine and Germany’s Lead Discovery Center, is developing an oral drug to treat metastatic triple-negative breast cancer that no longer responds to currently available therapies.

This type of aggressive cancer spreads from the breast to other areas of the body, such as the bones, liver, lungs or brain. Roughly 38,000 to 57,000 Americans are diagnosed each year with metastatic triple-negative breast cancer. One study showed about half of patients survive past the one-year mark following diagnosis and about one-third survive two years.

“Baylor College of Medicine’s laboratories produce discoveries with the potential to change patients’ lives, and too many of them stall where academic funding ends and private investment has not yet begun,” Dr. Jakub Tolar, president, CEO and executive dean of the Baylor College of Medicine, said in a press release. “The BCM Legacy Fund fills that gap, giving our scientists a path to advance their discoveries to patients.”

The National Institutes of Health awards more than $36 billion per year for biomedical research in the U.S., Baylor said. But some biomedical discoveries “never leave the starting line because they don’t yet fit the economics of venture capital,” the college said.

“The forefront of a new model”

The BCM Legacy Fund aggregates philanthropic capital from private foundations and donor-advised funds. It then invests in startups so they can move beyond that starting line and into later-stage investment rounds. The Greater Houston Community Foundation is the fund’s philanthropic partner.

“It’s exciting to be on the forefront of a new model for philanthropic capital,” said Houston entrepreneur and investor Burton Hanson, managing partner of the fund.

“Not only do we hope to solve a real problem by advancing these therapies to the patients who need them most, but we also hope this model will inspire others in the city and beyond toward philanthropic creativity and a posture of ‘I sacrifice; we win.’”

The fund expects to invest in about 15 early-stage startups over a five-year span. Baylor declined to divulge the amount of money in the fund and the size of the investment in Nemea.

Nemea’s “world-class chemistry”

Hanson oversees the Baylor fund alongside Chicago investor Steve Lehmann, who led the University of Chicago’s Innovation Fund.

Lehmann said Nemea, the fund’s first portfolio company, “has world-class chemistry, Baylor biology, and patients with no good options. Our job is to fund the experiments that carry it to the next handoff, so that industry and later-stage investors can take it from there.”

Based at Houston’s massive Texas Medical Center, Nemea plans to start clinical trials next year in collaboration with Baylor’s Lester and Sue Smith Breast Center.

Nemea previously received $9 million from the Lead Discovery Center and a $1.6 million grant from Baylor. Last year, the startup said it was seeking $25 million to $30 million in seed and Series A funding.

Debra McCoy of Houston, a former managing director at BlackRock and former partner at Bain & Co., and Paul Thomas, co-founder and CEO of Spring-based benefits manager Luscinia Health, sit on the Baylor fund’s governing board. Dr. Paul Klotman, former president, CEO and executive dean of Baylor, is a senior strategic adviser.

How does the fund find investment targets?

The Baylor Legacy Fund relies on two tools to help unearth early-stage biotech startups:

  • High-resolution “innovation maps” of research institutions. These maps surface hidden clusters of innovation, identify rising-star researchers and tie pockets of “innovation supply” at Baylor to areas of “innovation demand” in biotech.
  • AI-enhanced due diligence. AI agents assist with due diligence of early-stage biotech startups. The fund says the platform “distills the frameworks we’ve developed over a decade of teaching and investing into a flexible … diligence environment.”
The report considered patents, NIH funding, lab space, venture capital investments and the number of jobs. Photo via Pexels

Houston named the No.1 emerging city for biopharma in inaugural report

Biopharma Leader

Houston is ranked No.1 on the first-ever Next 10 U.S. Biopharma Clusters report published by Genetic Engineering & Biotechnology News (GEN).

The report, which ranks the best emerging hubs for life science activities, considered patents, NIH funding, lab space, venture capital investments, and the number of jobs in regions in cities, states and “clusters” across the U.S. GEN touts Houston as the top city for the biopharma industry due to a surge in funding, job creation, medical innovations and startup success.

Here’s how Houston ranked in the report’s different categories;

  • No. 1 for NIH funding with 2,262 awards totaling more than $1.25 billion
  • No. 2 for emerging regions for jobs, with 28,000 jobs
  • No. 2 for lab space, with roughly 8 million square feet in the market
  • No. 6 for patents, with 2,760 patent families

According to BioHouston chairman Jeff Wade, Houston secured half a billion dollars in venture capital funding in 2025 and 2026 to date.

The report called out major biopharm news out of Houston in the last few months, including Bristol Myers Squibb selecting Houston for its $1 billion, 600,000-square-foot manufacturing site and Eli Lily selecting Houston for its $6.5 billion, 236-acre manufacturing site. Both facilities will be located within Generation Park, a 4,300-acre, master-planned commercial district near Lake Houston.

Houston startups like CrossBridge Bio and Duracyte were also mentioned in the report. CrossBridge, which develops antibody-drug conjugates for cancer, was acquired by Eli Lily in April for $300 million. Duracyte, a “living pharmacy” company, was launched out of Rice University’s biotech venture studio RBL LLC this spring and is backed by up to a $45 million Advanced Research Projects Agency for Health (ARPA-H) award.

The startup is working to commercialize its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR) technology, a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time.

“There’s a lot of great talent, but the unique advantage that we have is we are able to benefit from a lot of unique clinical infrastructure and clinician insights,” Omid Veiseh, Duracyte co-founder and managing partner of RBL LLC, told GEN. “There are a lot of clinicians here who are eager to partner on investigator-initiated trials.”

The report also touted Houston’s Texas Medical Center, home to the University of Texas MD Anderson Cancer Center and Baylor College of Medicine, and international partnerships like the recently expanded TMC Korea BioBridge.

Other cities to make the list include:

  • No. 2 Minneapolis-St. Paul
  • No. 3 Denver-Boulder
  • No. 4 St. Louis
  • No. 5 Dallas-Fort Worth

States to make the list include:

  • No. 1 Ohio (including Cincinnati, Cleveland, and Columbus)
  • No. 2 Indiana (including Indianapolis)
  • No. 3 Florida (including Jacksonville and Miami-Fort Lauderdale)
  • No. 4 Georgia (including Atlanta and Augusta)
  • No. 5 Wisconsin (including Madison and Kenosha)

Regional state clusters to watch include:

  • Phoenix
  • Pittsburgh
  • Greater Richmond, Virginia
  • South Carolina
  • Utah

See the full report here.

BCM ranks as the 144th best university in the world. Photo via BCM.edu

5 Houston universities named best in the world on new U.S. News list

Top of the Class

Five Houston-area universities have been named among the best universities worldwide in U.S. News & World Report's just-released comprehensive list for 2026-2027.

U.S. News' Best Global Universities report ranks more than 2,250 schools based exclusively on their academic research performance and international reputation. Only 275 universities from the U.S. were included in the global ranking, and 21 based in Texas.

Harvard University topped the list for 2026-2027, and the Massachusetts Institute of Technology and Stanford University claimed the coveted No. 2 and No. 3 spots worldwide.

Houston's Baylor College of Medicine topped the list of the best local schools, and it ranked as the 144th best university in the world.

Here's how the rest of Houston's local institutions ranked:

  • No. 201 – Rice University
  • No. 324 – University of Texas Health Science Center Houston
  • No. 390 – University of Houston
  • No. 599 – University of Texas Medical Branch Galveston

In a statement explaining global university trends, the managing editor for Education at U.S. News, LaMont Jones, Ed.D., said schools in the U.S. have continued to rank "disproportionately high" while major universities from other countries in China and South America are starting to catch up.

"The continuing strength of [American university] reputations and academic research are, for the most part, unmatched," he said. "It's why students all over the world flock here to learn."

Top-ranking Texas universities
The University of Texas at Austin ranked No. 1 statewide and No. 56 worldwide, further cementing the university's reputation as the top choice for students seeking a higher education in Texas.

Earlier in June, UT Austin ranked No. 35 in a separate list of the best universities in the world from the Center for World University Rankings, which compared 2,000 schools globally.

Here's where other Texas universities stand among the top 1,000 in this year's global rankings:

  • No. 113 – University of Texas Southwestern Medical Center, Dallas
  • No. 177 – Texas A&M University, College Station
  • No. 296 – University of Texas at San Antonio
  • No. 451 – Baylor University, Waco
  • No. 503 – University of Texas at Dallas
  • No. 562 – Texas Tech University, Lubbock
  • No. 739 – University of North Texas, Denton
  • No. 975 – University of Texas at Arlington
  • No. 944 – Southern Methodist University, Dallas
Additionally, six Texas universities ranked outside the top 1,000: University of Texas Rio Grande Valley (No. 1,153); University of Texas El Paso (No. 1,238); Texas State University in San Marcos (No. 1,531); Texas Tech University Health Sciences Center in Lubbock (No. 1,871); Texas Christian University in Fort Worth (No. 1,906); and Sam Houston State University in Huntsville (No. 2,141).

---

This article originally appeared on CultureMap.com.

The Cancer Prevention and Research Institute of Texas has awarded its latest round of grants. Photo via tmc.edu

4 Houston-area institutions get $8M for cancer research facilities

fighting cancer

Cancer research capabilities in the Houston area just got an $8 million boost.

On Wednesday, May 20, the Cancer Prevention and Research Institute of Texas (CPRIT) awarded $8 million in grants to institutions in Houston and Bryan for the creation or expansion of so-called “core” cancer research facilities.

“Core facilities provide shared access to advanced technology, equipment, and scientific expertise that may not be available at every institution,” CPRIT says. “These core facilities are vital to not only cancer research but also to the study of diseases beyond cancer.”

Houston-area recipients of these $2 million grants are:

  • A facility at the University of Texas Health Science Center for preclinical support of cancer researchers in Texas to evaluate new safe, effective drugs and drug combinations.
  • The Accelerator for Cancer Therapeutics, operated by Houston’s Texas Medical Center Foundation. The accelerator helps researchers and startups move innovative cancer treatments from the lab to clinical trials.
  • Rice University’s Genetic Design & Engineering Center in Houston. The center enables researchers to collaborate on studies of custom DNA for cancer treatment.
  • A facility at the Texas A&M University System’s Health Science Center in Bryan that aims to speed up the development of cancer therapies.

In addition to those grants, the University of Texas M.D. Anderson Cancer Center, Methodist Hospital Research Institute, Baylor College of Medicine, and Rice University shared $21 million to recruit cancer researchers from other institutions.

The largest of those grants—totalling $4 million—went to M.D. Anderson for the recruitment of renowned cancer researcher Andre Nussenzweig from the National Institutes of Health. His research focuses on how DNA damage and faulty DNA repairs lead to cancer.

Here are the totals for the other CPRIT grants awarded in the Houston area:

  • $12.8 million to Houston-based Indapta Therapeutics for the development of an off-the-shelf therapy that naturally kills cancer cells, combined with an immunity-targeting agent for a type of leukemia.
  • $11.1 million to MD Anderson, including $5 million for a statewide platform to improve long-term health outcomes in adolescents and young adults who survived cancer.
  • $8.4 million to Baylor College of Medicine, including $4.8 million for two training programs for cancer researchers.
  • $6.25 million to UT Health Houston, including $4 million for a biomedical informatics and genomics training program for cancer researchers.
  • $4.4 million to the Texas A&M Health Science Center’s Houston campus, including $2.4 million for a cancer therapeutics training program.
  • $2.75 million to Rice, including $250,000 for a study of ovarian cancer.
  • $2 million to Houston-based March Biosciences for the development of a targeted therapy for treating T-cell lymphoma.
  • $1.15 million to the University of Houston, including $900,000 for a platform for detection of lung cancer.
  • $900,000 to Texas A&M in Bryan to conduct clinical drug trials in rural and underserved communities around the state.
  • $800,000 to Houston- and Israel-based Xerient Pharma for the development of an oral form of a cell-protecting drug called amifostine to protect the upper GI tract from radiation damage during pancreatic cancer treatment.
  • $659,000 to Missouri City-based OmniNano Pharmaceuticals for the development of a two-drug combination to treat the most common form of pancreatic cancer.
  • $250,000 to the University of Texas Medical Branch at Galveston for a novel therapeutic to prevent colitis-related colorectal cancer.
Motif Neurotech is developing minimally invasive bioelectronics to treat psychiatric conditions. Photo via motifneuro.tech

Houston startup’s brain implant for depression advances to clinical trial

moving forward

Houston-based Motif Neurotech has received FDA approval to move forward with its first clinical trial for its innovative way to fight treatment-resistant depression and other mental health disorders.

The company has developed a brain-computer interface technology based on research from Rice University. The blueberry-sized, wirelessly powered implantable device known as the Digitally-programmable Over-brain Therapeutic (DOT) stimulator delivers electrical stimulation to brain circuits linked to depression. The DOT stimulator sits in the skull above the dura without touching the brain and is considered an alternative to transcranial magnetic stimulation, which requires multiple treatment sessions and can cause headaches.

“The goal for this technology is that it would be the mental health equivalent of a continuous glucose monitor for diabetes,” Jacob Robinson, a Rice University professor of electrical computer engineering and bioengineering and CEO of Motif Neurotech, said in a news release. “What has been really special for me personally on this journey is to be able to work all the way from a concept through the process of research and development funded by the federal government at Rice, and take that into a product that is going to affect people’s lives for the better.”

Eligible adults whose depression has not improved after trying multiple therapies can take part in the study. The clinical trial will be conducted in collaboration with Baylor College of Medicine, Brain Health Consultants (Houston), UT Health Houston, Massachusetts General Brigham, Emory Healthcare, University of Iowa, University of Utah Health and New York University, according to Rice.

Motif also announced that it was one of the first teams selected for ARPA-H’s EVIDENT initiative, which recently awarded up to $139.4 million to spur new, effective therapies for behavioral health. Through the initiative, Motif will collect additional data alongside its clinical trial.

“The idea with this funding is to support a number of teams who have rapid-acting interventions for a mental health condition and to collect additional data to help determine with greater precision whether a treatment is working, how it is working and which patients are benefitting most from which course of treatment,” Robinson added in the release.

Motif Neurotech was spun out of Robinson’s and Professor Kaiyuan Yang’s labs at Rice, along with collaborators and co-founders Dr. Sameer Sheth at Baylor College of Medicine and Dr. Sunil Sheth at the University of Texas Health Science Center at Houston. It was founded through the Rice Biotech Launch Pad. The company closed its Series A round with an oversubscribed $18.75 million last year.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Announcing the winners of the 2026 Houston Innovation Awards

The winners are...

After weeks of anticipation, InnovationMap is proud to unveil the winners of the 2026 Houston Innovation Awards, our sixth-annual program honoring the best and brightest in the local innovation community.

This year, the Houston Innovation Awards recognized more than 40 finalists in 10 categories. They are shaping the future of Houston innovation across a variety of industries — from deep tech and energy to healthcare and education.

Finalists and winners were determined by our esteemed panel of judges, comprised of 2025 award winners, as well as InnovationMap editorial leadership. One winner was determined by the public via an online competition: Startup of the Year.

In the weeks leading up to this announcement, InnovationMap shined a spotlight on all of this year's outstanding finalists in our special editorial series. Learn more about all of them — and their outstanding achievements — here.

Without further ado, here are the 2026 Houston Innovation Awards winners:

Minority-founded Business: HexaSpec

Rice University spinout HEXASpec is working to improve the sustainability and thermal conductivity of semiconductor chips. The company has developed breakthrough inorganic fillers that allow graphic processing units (GPUs) to use less water and electricity and generate less heat. HEXASpec was founded in 2025 by CEO Tianshu Zhai, CTO Jing Zhang, and chief product officer Chen-Yang Lin. It has raised $800,000 in pre-seed funding and another $1.5 million in non-dilutive grants. The startup won the Liu Idea Lab for Innovation and Entrepreneurship's H. Albert Napier Rice Launch Challenge in 2024 and the 2025 Energy Venture Day and Pitch Competition during CERAWeek in the TEX-E student track in 2025. It was awarded a $500,000 National Science Foundation Partnership for Innovation grant last summer.

Female-founded Business: ARIX Technologies

Energytech startup ARIX Technologies has developed a semiautonomous VENUS crawler robot to detect corrosion under insulation before it becomes a failure. The robots climb insulated piping in refineries, chemical plants, and energy facilities to capture inspection data without removing insulation or building scaffolding. ARIX's inspection portal then turns information from the inspection into data a company can act on. ARIX was founded in 2017 by Dianna Liu, who serves as director, and Head of Product Petter Wehlin. Craig Malloy serves as CEO. The company has raised more than $22 million in seed funding and a Series A round.

Health Tech Business: Prana Surgical

Prana Surgical is developing a minimally invasive surgical platform for small, hard-to-reach lung nodules that may be cancerous. The company's Prana System cleared U.S. Food and Drug Administration (FDA) approval earlier this year. Prana Surgical was originally founded as Prana Thoracic in 2022. It has participated in numerous accelerators, including the Texas Medical Center Innovation Accelerator in 2023 and the IGNITE Health accelerator in 2022. It raised $6 million in Series A funding rounds in 2023 and 2024, with a Series B currently ongoing. The company is currently moving into the next stage of clinical validation and revenue generation in the U.S., in addition to preparing its manufacturing and commercial infrastructure for broader use.

Deep Tech Business: Venus Aerospace

Spacetech company Venus Aerospace is developing a high-thrust rotating detonation rocket engine (RDRE) that replaces the subsonic combustion used in conventional rocket engines. The RDRE is a compact, simpler engine that can deliver up to 15 percent greater efficiency for defense and space applications. It completed its first U.S. flight test of the engine last summer. Venus Aerospace was founded in 2020 by CEO Cassie Duggleby and CTO Andrew Duggleby. It raised a $20 million Series A in 2022 and $42 million Series A2 in 2025. It closed a $91 million Series B earlier this year and expanded its leadership team. The company is working toward longer-duration and higher-thrust testing and advancing its flight program.

Energy Transition Business: Hertha Metals

Hertha Metals produces lower-cost, lower-emission steel and high-purity iron. The company has developed a single-step process that uses natural gas as a direct reductant instead of metallurgical coal, which cuts production costs by more than 25 percent and emissions by up to 50 percent, according to the company. The same process produces high-purity iron needed for high-purity steels and rare earth magnets. The company says it aims to "re-industrialize America’s production of critical materials."

Scaleup of the Year: Hertha Metals

Founded by CEO Laureen Meroueh in 2022, Hertha Metals emerged from stealth in 2025 with more than $17 million in venture capital funding. The company closed a $133.65 million Series A in October and also broke ground on its $100M high-purity iron factory known as Chalyx in Conroe.

Incubator/Accelerator of the Year: Activate

Hard tech incubator Activate supports scientists in "the outset of their entrepreneurial journey." The Houston hub was introduced in 2024, and joins others in Boston, New York, and Berkley, California—where Activate is headquartered. It named its third Houston cohort this summer. The two-year program graduated its first class of Houston fellows in 2026 and saw its first alumni IPO from Houston-based Fervo Energy, which previously participated in a Berkley cohort. Nationally, it has supported 346 fellows and 276 companies since 2015. Those companies have raised more than $6 billion in follow-on funding, according to Activate. In Houston, it has supported local startups like Solidec, FlowCellutions and Orbital Arc. Activate Houston is led by managing director Jeremy Pitts, who co-founded Greentown Labs in Boston. It is based out of the Ion.

Startup of the Year (People's Choice): Progress Report

Progress Report is a K-12 learning-intelligence platform designed to go beyond identifying that a student is struggling. It traces performance to learning gaps and prerequisite skills, helping educators understand where a student is struggling and what may be causing it. Progress Report recently released a fully built production platform and launched pilots with 35 educators and 200 students across Texas and Arizona.

Mentor of the Year: Kyle Judah, Liu Idea Lab at Rice University

Kyle Judah is the executive director of Lilie, where he mentors pre-seed student startups. He also mentors through organizations like TEX-E, Greentown Labs and Activate. Some of the startups he's mentored include Helix Earth Technologies, Tierra Climate, Solidec, HexaSpec, SteerBio and many others.

"[Being a mentor] means helping to ensure that the most people possible have the best shot possible at making their company a successful reality," Judah says. "It means, at its root, opening the aperture for what is possible for people, by believing in them before anyone else even understands what their ambitions are. Because belief is the most infectious thing in the world. And before digging into the work in the trenches, most times founders need to kickstart their journey by having someone from the outside believe in them, when there's no real evidence to support that belief. So I guess, mentorship is a pure form of entrepreneurial faith."

2026 Trailblazer Legacy Award: Don Kendall Jr.

This year, the Trailblazer Legacy Award is given posthumously to Don Kendall Jr., who died in September while on a trip to the Republic of the Congo with the Jane Goodall Institute, one of the many organizations he was deeply involved with. Kendall served as general partner of New Climate Ventures, a Houston-based early-stage venture capital firm that invests in next-gen energy, materials and fuel technologies and startups. The firm's portfolio includes Houston-based clean energy companies like Solidec, Syzygy Plasmonics and Rheom Materials.

Outside of the clean energy space, Kendall also served on the boards of the Jane Goodall Institute, Earthwatch International and Ecological Defense Group. He also served as vice chair of Houston Zoo Inc. and chair of its Conservation Committee. "[Don] paired a keen eye for potential with the relentless drive to unlock it. For Mars Materials, his early backing carried us through a critical valley when we needed belief the most, and his presence as a personal mentor is profoundly missed," says Innovation Awards judge Aaron Fitzgerald.

NASA leader calls SpaceX Starship's return from orbit 'almost magic'

Space news

SpaceX’s Starship made a triumphant return to Earth on Saturday, November 14, caught in midair by giant mechanical arms where its journey began 22 hours earlier.

It was the grand finale that Elon Musk and his team hoped for — the first-ever capture of a Starship flying back from space. But with the first-stage booster exploding shortly after Friday’s liftoff from Texas, the company fell short of its desired double catch, still the goal for accelerating moon and Mars travel.

Wreckage remained in the Gulf of Mexico, cordoned off by buoys, as the stainless steel, bullet-shaped spacecraft lowered itself upright at the launch pad.

The dramatic, sci-fi-like capture helped blot out the booster’s messy miss. Cameras panned the spacecraft up and down as it hung high above the ground, supported by the arms of the launch tower.

“Can you believe it?” SpaceX commentator Dan Huot shouted, dragging out each word. “Look at her! Baby, she’s back!”

Calling it an “epic day,” Musk later ascended the launch tower to take up-close video with his phone. He even hugged the spacecraft. “Looks great,” he reported via X.

SpaceX officials said the catch demonstrates the full reusability of Starship, crucial for rapid and low-cost recycling. Although Friday’s booster recovery failed, the company had already made three previous booster catches, validating the technique.

NASA welcomed Saturday’s news. The space agency is paying billions of dollars for Starship to land Artemis astronauts on the moon later this decade and help build a permanent lunar base. Musk’s ambitions are even grander: He wants to launch a fleet of Starships to build a city on Mars.

“It was almost magic,” NASA Administrator Jared Isaacman said via X. “Making more believers by the day ... one step closer to (emojis of the moon and the U.S. flag)."

The world’s largest and most powerful rocket — a 407-foot (124-meter) behemoth — blasted off late Friday afternoon from SpaceX’s Starship base near the U.S.-Mexican border. Separating neatly from its booster before things went awry, the upper-stage spacecraft soared into orbit and released 26 advanced Starlink satellites.

Starship continued circling the world 165 miles (265 kilometers) up, with live views of itself and Earth streaming down via Starlink. The spacecraft completed 14 laps around Earth, outshining the previous mission’s one to two laps.

It was SpaceX’s 15th flight of a full-scale Starship since 2023 and its only second trip to orbit.

SpaceX reported that everything on the spacecraft, including its vital heat shield, appeared to work well.

As for the booster, SpaceX’s Kate Tice said its engines stopped firing too soon on the way back down. The booster’s guidance system sensed it wasn’t in the right position and automatically initiated the watery detour and self-destruction. Engineers are still investigating the cause.

SpaceX expects to begin launching Starships from Florida’s Kennedy Space Center within the next few months. That is the starting point for NASA’s next Artemis mission, which will skip the moon and remain in orbit around Earth for lunar lander practice.

Artemis III’s four astronauts will attempt to dock their capsule with not only Starship but Blue Origin’s Blue Moon. The two companies will take turns delivering crews to the lunar surface. NASA is targeting as soon as 2028 for Artemis IV, humanity’s first moon landing since the Apollo era more than half a century ago.

University of Houston med school secures full accreditation

med school milestone

The University of Houston’s Tilman J. Fertitta Family College of Medicine has officially earned full accreditation after launching six years ago.

The designation comes from the Liaison Committee on Medical Education, which granted UH the maximum five-year review period available to a new medical school. To achieve the status, the committee reviewed the Fertitta College of Medicine's facilities, faculty and student outcomes, and curriculum to ensure the college met the highest standards in medical education.

“Full accreditation is not the finish line — it’s the foundation for everything we hope to accomplish in the years ahead,” Dr. Jonathan McCullers, vice president for health affairs at UH and dean of the Fertitta College of Medicine, said in a news release. “It strengthens our ability to attract outstanding students and faculty, expand our partnerships and prepare the next generation of physicians.”

Fertitta College of Medicine has graduated three classes of physicians, and every graduate from its most recent class secured a residency position. Enrollment has expanded from 30 students in its inaugural class to 65 students in its current class.

According to UH, about 70 percent of graduates have chosen to remain in Texas for further training, which is key to addressing the estimated 10,000 doctors needed to meet growing needs.

Fertitta College of Medicine opened for its first students in 2020, and now joins 14 other Texas schools as a fully LCME-accredited medical school. It also joins UTHealth Houston's McGovern Medical School and Baylor College of Medicine as one of three Houston-based LCME-accredited campuses.

The news comes after UH launched its health enterprise initiative, UH Health, in July and broke ground on its $77.5 million Medical Research Building next to the Fertitta College of Medicine last month.

“Building a medical school from the ground up is an extraordinary undertaking, and this milestone reflects the dedication of everyone who helped make it happen,” Dr. Stephen Scott, vice dean for education at the Fertitta College of Medicine, added in the release. “From developing an innovative curriculum to establishing the systems and partnerships that support our students, this has been a true team effort.”